Repligen to acquire bioprocessing analytics portfolio of 908 Devices for $70m.

Repligen, a life sciences company focused on bioprocessing technology leadership, agreed to acquire bioprocessing analytics portfolio of 908 Devices, a provider of in purpose-built handheld and desktop devices for chemical analysis, for $70m. “Repligen’s leadership in commercializing innovative solutions that advance bioprocessing is a great fit for our novel desktop devices and our bioprocessing team. I wish them continued success. Going forward, 908 Devices will continue to advance chemical detection at the point of need with our handheld analytical devices in vital health and safety applications,” Kevin J. Knopp, 908 Devices CEO and Co-founder.